Company
Team
CORPORATE GOVERNANCE
Platforms
Glycovirology
Degenerative Diseases
pipeline
ProLectin Pipeline
Degenerative Disease pipeline
Resources
IN THE NEWS
Stroke video
faq
SCIENTIFIC PUBLICATIONS
investors
Company presentation
press releases
Reports
financial
Contact US
$BIXT
Company
Platforms
Glycovirology
Degenerative Diseases
Resources
Investors
Pipeline
contact us
Investors
Press releases
Company presentationS
Reports
financial
PRESS RELEASES
Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens
Bioxytran's collaboration with The University of Georgia will focus on evaluating Bioxytran’s galectin antagonist as a potential treatment for chickens infected with Bird Flu.
March 19, 2025
Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions
New water-soluble galectin antagonist being considered in preclinical trialsoffering hope for rapid containment to H5N1 outbreaks.
March 12, 2025
Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
BIOXYTRAN $BIXT announced it has entered into a common stock purchase agreement (the “SPA”) with TRITON FUNDS LP for $1,600,000.
January 22, 2025
see all
COMPANY PRESENTATIONS
CANCER METASTASIS
PRESENTATION
Clinical Trial Update
Investor Presentation
SCIENCE Presentation
LONG COVID PRESENTATION
Road to Ending the pandemic presentation
REPORTS
CRYSTAL RESEARCH
REPORT Update 12.21.22
Avise Analytics
Report 11.22.22
CRYSTAL RESEARCH
REPORT 7.26.22
FINANCIAL INFORMATION
press release
stock data
Historical Data
Historical stock Data
Investor presentation
sec filing
Documentation
presentation
fact sheet
charter of auditors
Avise Analytics Report